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To date, some functions of the lower urinary tract are not fully understood. Lower urinary tract disorders
such as lower urinary tract symptoms and overactive bladder are debilitating conditions with a negative
impact on quality of life. The major medical diseases, which have systemic effects on their victims, may
play a role in the disturbance of the lower urinary tract function. Recent studies provide further evidence
that a number of medical diseases such as chronic heart failure, chronic obstructive pulmonary disease,
constipation, chronic kidney disease, autoimmune diseases, and metabolic syndrome can affect the lower
urinary tract function via the disease mechanisms. Our aim was to summarize and analyze the results of
epidemiological surveys and recent advances in the understanding of systemic disease-related lower
urinary tract dysfunction. We expect our ﬁndings to indicate some areas for future research in this topic.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Micturition is a complicated process in which the coordination
of bladder relaxation in the ﬁlling phase and bladder contraction
and sphincter relaxation during the voiding phase is essential.1
These processes are regulated by vesical afferent and efferent
pathways and a neuropepetide control system, and the detrusor
contains multiple receptors and signaling pathways. Disturbances
in micturition function may result in lower urinary tract symptoms
(LUTS). LUTS is a group of urinary symptoms related to the storage,
emptying, and postmicturition phases.2 Aggravation of LUTS has a
profound impact on the patient’s quality of life.
LUTS typically develop as a result of primary bladder dysfunc-
tion or occur secondary to prostatic obstruction in the urological
ﬁeld. However, many diseases can affect lower urinary tract func-
tion by causing mechanical effects, urine overproduction, immune
reactions, peripheral nerve damage, pelvic vascular ischemia, and
visceroevesical interactions. In epidemiological studies, the prev-
alence of LUTS was found to be high in certain demographic groups
such as aged people, middle-aged women, and children.3 The
prevalent diseases in these populations may inﬂuence lower uri-
nary tract function via various disease mechanisms. In cases
involving diseases such as chronic heart failure (CHF), chronic
obstructive pulmonary disease (COPD), constipation, chronic kid-
ney disease (CKD), autoimmune diseases, and metabolic syndrome,siung Chang Gung Memorial
ity, Taiwan.
ee).
ciation. Published by Elsevier Taiwthe long-term and systemic effects of disease progression on lower
urinary tract function are overlooked by physicians and scientists.
Therefore, we conducted this review to compile the data on this
topic and identify the scope for further studies in this ﬁeld.2. CHF and LUTS
CHF is amedical condition inwhich the heart is unable to supply
sufﬁcient blood for tissue metabolism. The incidence of heart fail-
ure in persons aged more than 65 years can be as high as 10 cases
per 1000 population.4 Because ﬂuid retention and peripheral
edema in patients with CHF usually necessitate administration of
diuretics, these patients are also likely to experience changes in
urinary frequency. Certain risk factors for CHF, including hyper-
tension,5 diabetes mellitus,6 and obesity, also cause LUTS in aged
adults. Therefore, it would be of particular interest to determine the
interaction between CHF and the development of LUTS.
Nocturia, urinary incontinence, and overactive bladder (OAB)
are prevalent in patients with CHF. Fatigue, late-stage heart failure,
high body mass index, and diuretic use are associated with the
development of LUTS, particularly in patients showing symptoms
of OAB. When accompanied by hypertension and ﬂuid retention,
CHF may affect nocturia by inducing increased nocturnal urine
production. Additionally, Mckeique and Reynard5 suggested that a
reversal of the circadian rhythm results in a disorder of sodium
excretion in the elderly, which can cause nocturnal polyuria. They
also proposed the association between nocturnal polyuria and
heart failure. Arteriosclerosis and pelvic ischemia could be common
pathogenic factors for both CHF and OAB. Palmer et al7 reportedan LLC. Open access under CC BY-NC-ND license.
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with OAB in CHF patients because of the resultant dysfunction of
the autonomic nervous systems. Late-stage heart failure and con-
stipation also contribute to the presence of OAB symptoms. Chiu
et al8 further indicated that among patients with LUTS, storage
symptoms are more severe in patients who also have CHF, partic-
ularly in patients with a New York Heart Association Classiﬁcation
equal to or greater than class III. The role of diuretics in the
development of OAB in CHF patients is still a matter of debate
because ﬂuid overproduction related to diuretic use may not cause
urgency, which is the cardinal symptom of OAB. However, Ekun-
dayo et al9 showed that loop diuretics may increase the prevalence
of OAB symptoms in aged adults. Diuretic-induced rapid produc-
tion of urine may add urgency to diuretic-associated high urinary
frequency by triggering DO in the aging bladder.9
Patients with CHF experience OAB symptoms that can have a
negative impact on quality of life. Although the prevalence of OAB
in CHF patients is high (57%), few patients seek medical treatment
for their OAB.7 It should be noted that CHF patients with OAB may
have more severe cardiovascular comorbidities, including hyper-
tension, pulmonary heart disease, cerebrovascular disease, renal
disease, and diabetes.10 The antimuscarinics administered to pa-
tients showing CHF with OAB may result in an elevated heart
rate.11 An increased heart rate in these patients might reﬂect an
underlying autonomic imbalance, with increased sympathetic and
decreased parasympathetic tone, and could increase myocardial
oxygen consumption.11 Because of the negative effects of anti-
muscarinics on cardiovascular function, physicians should care-
fully evaluate the use of antimuscarinics for CHF patients with
OAB.
3. COPD and LUTS
COPD is a disease that can affect lower urinary tract dysfunction
by causing pharmacophysiological changes in bronchioles and
increased intra-abdominal pressure during chronic cough. The
manifestations of COPD include cough, chronic sputum production,
wheeze, and dyspnea.12 Chronic cough is the best single symptom
to predict airway obstruction in smokers older than 60 years13;
furthermore, chronic cough directly affects pelvic wall weakness
and aggravates urinary incontinence. Therapeutic agents for COPD,
such as inhaled beta-agonists, anticholinergics, and corticosteroids,
may also affect lower urinary tract function.
The international prevalence of COPD is 5% and 16% in patients
aged 40 years and older, respectively, and the prevalence depends
on the country in which the patient resides.14 The prevalence and
mortality rate of COPD patients have declined because of smoking
cessation and improving health care in recent decades.15 Several
large epidemiological studies indicated that different symptoms of
LUTS are associated with COPD in males and in females. Hirayama
et al16 reported that 10% of COPDmale patients older than 40 years
have urinary incontinence. Among patients with urinary inconti-
nence, 63% of men developed urgent incontinence. In another
community-based study, Jackson et al17 showed that 21% of women
may experience urinary incontinence at least once per week. Fe-
male COPD patients may show up to a 5.6-fold higher risk of stress
urinary incontinence.
The mechanisms underlying gender-based differences in LUTS
presentations are still unclear, and the management of LUTS in
COPD patients is a matter of debate as well. Hirayama et al18 sug-
gested an inverse association between urinary incontinence and
respiratory function in men. Thus, the use of beta-agonists to treat
COPD can improve 1st-second forced expiratory volume (FEV1)%
and decrease urinary incontinency in men with COPD. However,
cough is the major cause of urinary incontinency among 80e90% offemale with cystic ﬁbrosis.19 Frequent coughing and dyspnea may
lead to chronic ischemia and imbalance within the muscles of the
abdominopelvic capsule. Cough-related urinary incontinence is
common in patients with COPD and is largely overlooked. However,
this condition can signiﬁcantly alter the patient’s quality of life.
Systematic questioning by the physician would facilitate prompt
referral for appropriate therapeutic interventions, such as Kegel
exercise.
4. Constipation and LUTS
Constipation is a common medical condition among out-
patients. Constipation is deﬁned by less than three bowel move-
ments per week, with stools that are usually hard, dry, small in
size, and difﬁcult to eliminate. The prevalence of chronic idio-
pathic constipation is 14%.20 Anatomically, the rectum neighbors
the bladder, and they differentiate from a common embryological
origin in the cloaca.3 The motor nerve supply to each organ arises
from the same outﬂow, S2eS4; for example, the pudendal nerve
innervates both the anal and urethral striated sphincters. More-
over, the pelvic ﬂoor weakness caused by the severe straining that
arises from constipation may contribute to the development of
stress urinary incontinence. In epidemiological studies, re-
searchers reported that children, middle-aged women, and geri-
atric patients could be simultaneously affected by constipation and
LUTS.20e22
Functional constipation in the pediatric population is common,
with the prevalence ranging from 4% to 37% in different reports.21
Children with constipation have a higher prevalence of OAB,22 as
well as fecal and urinary incontinence,21 than children without
constipation. Loening-Baucke21 reported that 22.6% of American
children have constipation, and 9.1% of children with constipation
had coexisting daytime urinary incontinence. In contrast, the same
study showed that 3.9% of the children without constipation had
daytime urinary incontinence. In one study, with successful treat-
ment of constipation, the coexisting daytime incontinence was
resolved in 89% of these patients, and recurrent urinary tract in-
fections were avoided in all the affected children.23 In addition, in
neurologically normal children, treatment for urinary incontinence
reduced the prevalence of functional fecal incontinence from 32% to
21%.24
Constipation is also a bothersome medical condition that affects
12% to 32% of middle-aged women.3 Spence-Jones et al25 ﬁrst re-
ported that constipation is an important factor in the pathogenesis
of uterovaginal prolapse and stress urinary incontinence. Chronic
constipation was considered the second strongest predictor for
postpartum incontinence because of deteriorated support of the
pelvic wall. Females who had undergone laparoscopic/vaginal
hysterectomies or surgery for pelvic organ prolapse, or for urinary
incontinence, had nearly a 2-fold higher risk for obstructive defe-
cation.26 Additionally, aging is also an important factor that affects
constipation and LUTS. Charach et al27 reported that treatment for
constipation signiﬁcantly improved LUTS and the patient’s mood,
sexual activity, and quality of life.
Themutual interaction between constipation and LUTS seems to
be extensive and appears to be related to age. In pediatric patients,
for example, daytime incontinence, enuresis, and recurrent urinary
tract infections may be associated with chronic constipation that
should not be overlooked by physicians. In middle-aged women,
pelvic organ prolapse may result from the straining associated with
chronic constipation. Management of chronic constipation for such
conditions may beneﬁt patients by alleviating LUTS and improving
quality of life.3,22 Further studies on the neuropathic population are
necessary for understanding the vesical interaction between the
rectum and bladder.
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The incidence of CKD is greater in Taiwan because of the
increased prevalence of the leading causes of CKD, including hy-
pertension, obesity, and diabetes.28 The prevalence of CKD in
Taiwan was 9.3% in 2003. CKD may be regarded as a clinical model
of premature vascular aging. In the United States, fewer than 2% of
CKD cases progress to end-stage renal disease (ESRD). Dialysis and
renal replacement therapy are the therapeutic options for patients
with ESRD.
Some researchers have reported that patients with chronic renal
failure and those who had received kidney transplantation may
develop LUTS. Wu et al reported that about one-fourth of patients
with ESRD had moderate-to-severe LUTS as identiﬁed by the
American Urological Association Symptom Index, regardless of the
dialysis modality.29 In the same study, they also determined that
ESRD patients who receive peritoneal dialysis are more likely to
present with nocturia and abdominal straining than those treated
with hemodialysis. Zermann et al30 reported that the major uro-
dynamic ﬁndings in patients with ESRD are bladder oversensitivity,
poor bladder compliance, detrusor overactivity, and detrusor
sphincter dyssynergia. Oborn and Herthelius31 reported that chil-
dren and adolescents with chronic renal failure may suffer from
LUTS, including incontinence (20%) and discontinuous ﬂow (15%).
They suspected that the high frequency of urinary tract infections in
these patients may play a role in the development of LUTS.
The nature of LUTS after renal transplantation is another inter-
esting issue for physicians. After successful transplantation, urine
production is restored, and the lower urinary tract should adapt to
urination again. However, this back-to-normal process might cause
voiding dysfunction. Van der Weide et al32 reported that frequent
micturition, both during the day and at night, occurred in patients
who had received renal transplantation. After renal trans-
plantation, almost 50% of patients complained of high urinary fre-
quency and 62% reported nocturia. Over a 3-year follow-up period,
high urinary frequency and nocturia persisted among renal trans-
plant recepients.33 Mitsui et al34 reported that the majority of cases
of frequent urination may result from the polyuria and voiding
dysfunction observed in renal transplant recipients. The inﬂuence
of bladder dysfunction should be carefully observed in pediatric
recipients, because 18.6% of pediatric transplant patients presented
with a dysfunctional lower urinary tract.35 In the future, more
prospective studies that compare the change in bladder function
and LUTS before and after renal transplantationmay supply us with
valuable information to better understand the association between
CKD and LUTS.
6. Autoimmune diseases and LUTS
Autoimmune diseases result from an aberrant immune response
in which an organism fails to recognize its constituent parts and
initiates an immune response against its own tissue. There are
several notable autoimmune diseases in humans, including sys-
temic lupus erythematosus (SLE), Sjögren’s syndrome, and rheu-
matoid arthritis. Autoimmune disease can directly affect the lower
urinary tract function by attacking the central nervous system,
upregulating the peripheral neurotransmission receptors, or
depositing immune complexes in the bladder.
SLE is a systemic autoimmune disease that involves the pro-
duction of antinuclear antibodies. These antibodies result in im-
mune complexes attaching tomajor organs or connective tissue. SLE
can cause interstitial cystitis-like syndrome, with a prevalence of
approximately 1e2%. In severe cases, bilateral vesicoureteral ste-
noses causing hydronephrosis are present. The development of
lupus cystitis may be associated with lupus enteritis.36 Theseconditions may share similar abdominal and urinary symptoms,
and both may respond to treatment with steroids or cyclophos-
phamide. An increase in serum anti-dsDNA levels has been reported
to be one of the causes of severe lupus cystitis.37 In epidemiological
studies, researchers reported that patients with SLE may present
with a variety of urinary symptoms, including high urinary fre-
quency, urgency, weak stream, and incomplete emptying.38,39 The
increase in disease activity and central nervous system involvement
in cases of SLE may be associated with the presence of LUTS. Uro-
dynamic studies of SLE patients with LUTS may show a low cysto-
metric bladder capacity that reveals the presence of a contracted
bladder due to immune-complex deposition.
Sjögren’s syndrome, which arises from an autoimmune process
affecting the lacrimal and salivary glands, presents with dryness of
the eyes andmouth in affected patients. It may occur either alone or
within the context of another autoimmune disease, such as rheu-
matoid arthritis or SLE. Patients with primary and secondary
Sjögren’s syndrome may have autoantibodies that attack the M3
muscarinic receptor in the bladder.40 Walker et al41 reported that
patients with primary Sjögren’s syndrome may suffer from more
severe urinary urgency than those with osteoarthritis. In an animal
study, passive transfer of Sjögren’s syndrome IgG of humans into
mice antagonized the M3 muscarinic receptor and produced a
compensatory increase in M3 muscarinic receptor expression in
mice bladder.40 This mechanism is considered to be the cause of
OAB syndrome observed in humans with Sjögren’s syndrome. In
addition, patients with rheumatoid arthritis with secondary Sjög-
ren’s syndrome may show an increased risk of LUTS, especially
urination frequency, in comparison with normal individuals.42
7. Metabolic syndrome and OAB
Metabolic syndrome consists of the risk factors for cardiovas-
cular disease, including diabetes, insulin resistance, central obesity,
dyslipidemia, and hypertension. The core elements of metabolic
syndrome are reportedly diabetes, prediabetes, insulin resistance,
and central obesity. Recent studies have provided signiﬁcant sup-
port for a relationship between the presence of metabolic syn-
drome and OAB.
In an epidemiological study, Rohrmann et al43 reported that
men showing components of metabolic syndrome had an increased
risk of nocturia, incomplete bladder emptying, weak stream, and
hesitancy. Yu et al44 also indicated that hyperlipidemia is associated
with OAB in Taiwanese women. Furthermore, obesity alone or
combined with diabetes can precipitate lower urinary tract dys-
functions such as OAB and stress urinary incontinence in females.45
These ﬁndings demonstrate that the major presentations of meta-
bolic syndrome can be associated with OAB. The core characteris-
tics of metabolic syndrome, including diabetes, insulin resistance,
and obesity, have been proposed to affect LUTS through the nitric
oxide synthase/NO system, autonomic hyperactivity, Rho-kinase
activation, and pelvic atherosclerosis.46
Animal studies suggest a link between the characteristics of
metabolic syndrome and OAB. In an animal model of metabolic
syndrome induced by fructose feeding, Tong and Cheng47 reported
that upregulation of M2,3 muscarinic receptors in the bladder was
associated with the presentation of DO. The metabolic perturba-
tions induced by long-term fructose feeding also contributed to DO
and OAB symptoms, including proinﬂammation, increased oxida-
tive stress, mitochondrial dysfunction, high levels of apoptosis in
the detrusor muscle, and detrusor hypertrophy.48,49 In progressive
hypertension and hyperlipidemia in a spontaneously hypertensive
and hyperlipidemic rat model, Nobe et al50 also showed decreased
rho kinase and protein kinase activities, both of which weaken the
contractility of the detrusor.
Fig. 1. How do medical diseases affect lower urinary tract function? CHF ¼ chronic
heart failure; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary
disease; MS ¼ metabolic syndrome.
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in cases of metabolic syndrome. Research conducted on a chronic
hyperlipidemic rabbit model revealed that heritable hyperlipid-
emia can cause reduced bladder capacity, DO, and nerve degener-
ation of the bladder.51 This observation could explain the
aggravation of OAB symptoms along with hyperlipidemia observed
in the human study.44
Oxidative stress may be induced by overexercise of the detrusor
in the course of repeated DO and frequent urination.49 In the early
stages of bladder hyperactivity, the mitochondrial apparatus can
supply the required high energy consumption. In the long run,
however, the excessive energy demand and stimulation could
exhaust the mitochondrial respiratory chain and impair its energy
transduction system. Under such circumstances, oxidatively
strained mitochondria become deformed and turn into a source of
reactive oxidative stress, which initiates a self-destructing process
in the mitochondrial respiratory apparatus, leading to protein
damage, detrusor dysfunction, and, ultimately, atrophy.
In sum, through similar causative mechanisms, animal models
mimicking metabolic syndrome may be predisposed to OAB and
bladder dysfunction.8. Conclusion
In this review of the literature, we have demonstrated that
diseases have a strong impact on the presentation of LUTS. We
illustrate the inﬂuence of various diseases in Fig. 1. CHF and the use
of diuretics may result in OAB syndrome. The prevalence of OAB
symptoms in CHF patients is associated with the severity of the CHF
present. COPD may cause urgent incontinence in males, but stress
urinary incontinence in females occurs because of theweakening of
the pelvic ﬂoor. Constipation is associated with the urinary incon-
tinence and recurrent UTIs in children. Treating the constipation
would be beneﬁcial for the improvement of urgent incontinence in
children. The inﬂuence of autoimmune diseases and metabolic
syndrome on the lower urinary tract function is comprehensive.
Neurogenic insults, vasculopathy, and myopathy in autoimmune
disease and metabolic syndrome may contribute to lower urinary
tract dysfunction. Although a deﬁnite treatment for LUTS-related
diseases has not been identiﬁed, clinicians should not neglect the
impact of various diseases on LUTS. Further studies are needed toclarify the relationship between lower urinary tract dysfunction
and major diseases.
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